A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and Have Progressed on First Line IRESSA
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMPRESS
- Sponsors AstraZeneca
- 06 Dec 2019 Status changed from active, no longer recruiting to completed.
- 06 Dec 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Planned End Date changed from 31 Dec 2018 to 30 Dec 2019.